Table 3

Clinical and serological findings in 24 patients with WG

Patient	Age	Sex	Diagnosis	State	Titre	Spec.	BVAS	CRP	VDI	WBC	Immunosuppressive treatment at time of analysis
1	28	f	WG	N	>640	Pr3	33	190	0	14.4	no
				Q	40	Pr3	0	<3	2	6.9	aza 150 mg + pred 10 mg
2	63	m	WG	N	>640	Pr3	39	149	2	11.5	no
				Q	80	Pr3	0	<3	2	6.5	pred 12.5 mg + CP 75 mg
3	85	m	WG	N	160	Pr3, HLE	27	99	1	8.0	no
4	36	f	WG	N	80	Pr3	8	5	0	7.6	no
5	38	f	WG	R	>640	Pr3	17	32	5	6.0	CP 75 mg, pred 20 mg
6	56	m	WG	R	160	Pr3	7	13	3	6.0	no
7	35	m	WG	R	160	Pr3	17	166	0	15.7	pred 20 mg
				Q	20	Pr3	0	11	1	7.5	pred 2.5 mg + aza 150 mg
8	63	m	WG	R	320	Pr3	11	47	2	4.4	no
				Q	20	Pr3	0	44	3	8.7	pred 10 mg
9	76	f	WG	R	160	MPO	9	108	7	7.5	no
10	49	m	WG	R	80	Pr3	6	4	1	6.8	no
				Q	40	Pr3	0	4	2	6.8	no
11	56	f	WG	N	320	Pr3	19	55	0	18.6	no
				Q	20	Pr3	0	3	1	8.0	pred 10 mg + CP 100 mg
12	75	m	WG	R	160	Pr3, MPO	7	17	2	5.8	no
				Q	40	Pr3, MPO	0	8	2	10.5	pred 7.5 mg
13	63	f	WG	R	80	HLE	3	8	2	5.2	pred 5 mg + aza 100 mg
14	48	f	WG	N	320	Pr3	20	118	0	13.4	no
				Q	0	Pr3	0	<3	0	4.1	aza 125 mg + pred 20 mg
15	54	f	WG	R	80	Pr3	1	92	3	12.4	no
16	51	f	WG	N	>640	MPO, HLE	19	22	0	3.6	no
17	27	m	WG	N	320	Pr3, LF	15	40	0	9.4	no
				Q	40	LF	0	52	1	9.7	pred 20 mg + aza 150 mg
18	44	m	WG	N	320	LF	11	5	0	5.2	no
				Q	80	LF	0	5	2	8.1	pred 32.5 mg + CP 50 mg
19	79	f	WG	N	320	Pr3	31	81	0	8.9	no
20	23	f	WG	R	320	MPO	10	<3	2	4.9	aza 75 mg
21	72	f	WG	R	160	MPO	12	<3	2	7.8	no
22	25	f	WG	N	40	Pr3	20	105	0	13.1	no
23	48	m	WG	R	80	Pr3	13	20	2	5.1	no
24	69	m	WG	N	320	Pr3	28	23.0	0	178	no

aza, azathioprine; CRP, C reactive protein (mg/l); CP, cyclophosphamide; HLE, human leucocyte elastase; MPO, myeloperoxydase; N, newly developed disease; nt, not tested; pred, prednisolone; Pr3, proteinase 3; Q, Quiescent disease; R, relapse; spec., ANCA specificity; titre, ANCA titre; WG, Wegener’s granulomatosis; WBC, white blood cell count (×10⁹/l).